Published in Int J Clin Oncol on March 16, 2010
Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol (2011) 1.30
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol (2013) 1.27
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med (2012) 1.03
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst (2012) 1.01
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis (2013) 0.98
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med (2012) 0.97
The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer (2013) 0.96
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol (2011) 0.95
The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol (2013) 0.92
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol (2015) 0.87
Malignant clinical features of anaplastic gliomas without IDH mutation. Neuro Oncol (2014) 0.83
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Neurosurg Rev (2013) 0.82
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs (2013) 0.79
Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev (2011) 0.78
Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker. Onco Targets Ther (2015) 0.75
MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion. J Neuropathol Exp Neurol (2016) 0.75
Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis. Cancer Manag Res (2017) 0.75
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Sci Rep (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest (2007) 2.06
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res (2004) 1.92
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol (2008) 1.74
Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol (1997) 1.68
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg (1993) 1.64
Glioblastoma multiforme: a clinical survey. J Neurosurg (1960) 1.61
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res (2005) 1.53
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol (1999) 1.52
MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol (2007) 1.42
MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol (2008) 1.40
Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol (2004) 1.17
Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach. Acta Neuropathol (2007) 1.13
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery (2009) 1.09
Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) (2009) 1.08
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res (2003) 1.08
Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol (2004) 1.07
The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg (2004) 1.04
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol (2007) 1.01
Long-term survival in patients with glioblastoma multiforme. Neurosurgery (1993) 0.98
Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology (2008) 0.95
O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer (2005) 0.93
MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics (2009) 0.88
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. Carcinogenesis (1996) 0.85
Long-term survival in patients with supratentorial glioblastoma. J Neurooncol (1998) 0.84
Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg (1988) 0.84
Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol (2004) 0.81
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest (2005) 3.02
Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial. Stroke (2014) 2.12
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Malignant peripheral nerve sheath tumor arising from benign vestibular schwannoma treated by gamma knife radiosurgery after two previous surgeries: a case report with surgical and pathological observations. World Neurosurg (2010) 2.09
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Efficacy of intraoperative wound irrigation for preventing shunt infection. J Neurosurg Pediatr (2008) 2.02
A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet (2010) 1.97
Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology (2006) 1.95
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
A partially ossified solid and cystic Rathke cleft cyst. J Neurosurg (2010) 1.65
Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol (2004) 1.61
A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke (2007) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci (2012) 1.54
Mechanisms of primary blast-induced traumatic brain injury: insights from shock-wave research. J Neurotrauma (2011) 1.50
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci (2009) 1.48
Hemodynamic analysis of growing intracranial aneurysms arising from a posterior inferior cerebellar artery. World Neurosurg (2011) 1.48
Additional surgery for postoperative ischemic symptoms in patients with moyamoya disease: the effectiveness of occipital artery-posterior cerebral artery bypass with an indirect procedure: technical case report. Neurosurgery (2009) 1.46
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
An analysis of flow dynamics in cerebral cavernous malformation and orbital cavernous angioma using indocyanine green videoangiography. Acta Neurochir (Wien) (2012) 1.43
Ectopic recurrence of craniopharyngioma. J Clin Neurosci (2005) 1.39
Cortical sensory map rearrangement after spinal cord injury: fMRI responses linked to Nogo signalling. Brain (2007) 1.38
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol (2005) 1.32
Identification of pendrin as a common mediator for mucus production in bronchial asthma and chronic obstructive pulmonary disease. J Immunol (2008) 1.30
Symptomatic spinal dissemination of malignant astrocytoma. J Neurooncol (2003) 1.29
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Minimum apparent diffusion coefficient is significantly correlated with cellularity in medulloblastomas. Neurol Res (2009) 1.21
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene (2005) 1.20
Seizure-induced thoracic spine compression fracture: case report. Surg Neurol (2002) 1.19
Temporary neurologic deterioration due to cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with adult-onset moyamoya disease. Surg Neurol (2007) 1.17
Acute pancreatitis due to pancreatic arteriovenous malformation: 2 case reports and review of the literature. Pancreas (2006) 1.16
Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol (2007) 1.14
Computational replicas: anatomic reconstructions of cerebral vessels as volume numerical grids at three-dimensional angiography. AJNR Am J Neuroradiol (2004) 1.12
Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci (2010) 1.11
Neuroprotective effect of an antioxidant in ischemic brain injury: involvement of neuronal apoptosis. Neurocrit Care (2005) 1.11
Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer (2013) 1.11
Glomangiopericytoma of the nasal cavity. Auris Nasus Larynx (2010) 1.10
Middle cerebral artery plaque imaging using 3-Tesla high-resolution MRI. J Clin Neurosci (2008) 1.09
Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) (2009) 1.08
The Tohoku Medical Megabank Project: Design and Mission. J Epidemiol (2016) 1.08
Computational simulation of therapeutic parent artery occlusion to treat giant vertebrobasilar aneurysm. AJNR Am J Neuroradiol (2004) 1.07
IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. Biochem Biophys Res Commun (2006) 1.07
Total-circumference intraoperative frozen section analysis reduces margin-positive rate in breast-conservation surgery. Jpn J Clin Oncol (2010) 1.07
Incidence and risk factors for symptomatic cerebral hyperperfusion after superficial temporal artery-middle cerebral artery anastomosis in patients with moyamoya disease. Surg Neurol (2008) 1.06
Pressure-dependent effect of shock waves on rat brain: induction of neuronal apoptosis mediated by a caspase-dependent pathway. J Neurosurg (2007) 1.05
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res (2006) 1.04
Radiologic-pathologic correlation of ductal carcinoma in situ. Radiographics (2010) 1.04
Cervical cord compression with myelopathy caused by bilateral persistence of the first intersegmental arteries: case report. Neurosurgery (2003) 1.03
Mutations in genes encoding the glycine cleavage system predispose to neural tube defects in mice and humans. Hum Mol Genet (2011) 1.03
Angiomyolipoma in the knee--a case report. Ups J Med Sci (2005) 1.02
Local hemodynamics at the rupture point of cerebral aneurysms determined by computational fluid dynamics analysis. Cerebrovasc Dis (2012) 1.02
Postoperative neurological deterioration in pediatric moyamoya disease: watershed shift and hyperperfusion. J Neurosurg Pediatr (2010) 1.01
Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma. Brain Tumor Pathol (2009) 1.01
Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg Neurol (2009) 0.99
Simultaneous occurrence of subarachnoid hemorrhage and cerebral infarction caused by anterior cerebral artery dissection treated by endovascular trapping. Neurol Med Chir (Tokyo) (2010) 0.99
Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci (2013) 0.99
Elevated risk of colorectal adenoma with Helicobacter pylori-related chronic gastritis: a population-based case-control study. Int J Cancer (2011) 0.99
Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg (2007) 0.99
Lipofibromatosis arising in a pediatric forearm--a case report. Ups J Med Sci (2005) 0.99
Congestive myelopathy due to cervical perimedullary arteriovenous fistula evaluated by apparent diffusion coefficient values - case report. Neurol Med Chir (Tokyo) (2006) 0.98
Intramedullary spinal tuberculoma--case report. Neurol Med Chir (Tokyo) (2004) 0.98
Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg (2008) 0.97
Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma. J Neurooncol (2004) 0.97
Functional MRI of the brain detects neuropathic pain in experimental spinal cord injury. Pain (2008) 0.97
Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol (2010) 0.97
[Epidemiology of chronic subdural hematomas]. No Shinkei Geka (2011) 0.96
Hypophysitis presenting with atypical rapid deterioration: with special reference to immunoglobulin G4-related disease-case report-. Neurol Med Chir (Tokyo) (2009) 0.96
Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci (2009) 0.96